INMB SEC Filings: 8-K, 10-Q, S-3 & 424B – INmune Bio

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

INmune Bio Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

Oct 29, 2026

8-K

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Oct 21, 2026

8-K

INmune Bio Appoints Biopharma Leaders R. Duane Clark II and James Sapirstein to Board of Directors

Sep 14, 2026

8-K

INmune Bio Receives $4.6 Million in R&D Tax Rebates

Jul 31, 2026

8-K

INmune Bio Inc. Announces Warrant Inducement and Maturity Extension

Jul 1, 2026

8-K

INmune Bio Receives MHRA Alignment for 2026 UK Conditional Marketing Authorization of Ebstrocel™ for RDEB

Jun 23, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Oct 29, 2026

424B5

December 2025 ATM | Offering amount: $65,000,000

Dec 19, 2025

424B5

REGISTERED OFFERING

Jun 30, 2025

424B5

Shares amount: 3,898,852 | Warrants amount: 3,898,852

Mar 7, 2025

424B5

Sep 16, 2024

424B5

ATM | Offering amount: $75,000,000

Aug 9, 2024

Registrations

TYPE

HEADLINE

FILED AT

8-A12B/A

Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]

Dec 8, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 13, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 13, 2025

8-A12B/A

Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]

Dec 9, 2024

S-3/A

SHELF | Offering amount: $250,000,000.00 | Float: 19,782,429 EFFECTIVE

Aug 2, 2024

S-3

SHELF | Offering amount: $250,000,000.00 | Float: 19,760,985 EFFECTIVE

May 1, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 14, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 3, 2025

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

May 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Clark Ronnie Duane (Reporting)

Sep 23, 2026

Clark Ronnie Duane (Reporting)

Sep 23, 2026

SAPIRSTEIN JAMES (Reporting)

Sep 17, 2026

SAPIRSTEIN JAMES (Reporting)

Sep 16, 2026

Juda Scott (Reporting)

Jul 7, 2026

Lowdell Mark William (Reporting)

Jul 7, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 8, 2024

CORRESP

Form CORRESP - Correspondence

Aug 5, 2024

CORRESP

Form CORRESP - Correspondence

Aug 1, 2024

CORRESP

Form CORRESP - Correspondence

Jul 30, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 3, 2024

LETTER

Form UPLOAD - SEC-generated letter

Apr 10, 2023

INmune Bio, Inc. INMB · SEC Filings